miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

PURPOSE: Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor A. It is currently used in combination with chemotherapy to treat metastatic colorectal cancer. This therapy is not equally effective in every patient; in some, mechanisms of resistance arise that remain p...

Descripción completa

Detalles Bibliográficos
Autores principales: Romero-Lorca, Alicia, Novillo, Apolonia, Gaibar, María, Gilsanz, María Fuencisla, Galán, Miguel, Beltrán, Laura, Antón, Beatriz, Malón, Diego, Moreno, Amalia, Fernández-Santander, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488031/
https://www.ncbi.nlm.nih.gov/pubmed/34616173
http://dx.doi.org/10.2147/PGPM.S313594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488031/
https://www.ncbi.nlm.nih.gov/pubmed/34616173
http://dx.doi.org/10.2147/PGPM.S313594

Ejemplares similares